PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2017 January 24; 8(4): 5895–5908.
Published online 2016 December 13. doi:  10.18632/oncotarget.13927
PMCID: PMC5351599

Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells

Abstract

Recent studies have shown that high ATP levels exhibit direct cytotoxic effects on several cancer cells types. Among the receptors engaged by ATP, P2×7R is the most consistently expressed by tumors. P2×7R is an ATP-gated ion channel that could drive the opening of a non-selective pore, triggering cell-death signal. We previously demonstrated that acute myeloid leukemia (AML) cells express high level of P2×7R. Here, we show that P2×7R activation with high dose ATP induces AML blast cells apoptosis. Moreover, P2×7R is also expressed on leukemic stem/progenitor cells (LSCs) which are sensitive to ATP-mediated cytotoxicity. Conversely, this cytotoxic effect was not observed on normal hematopoietic stem/progenitor cells (HSCs). Notably, the antileukemic activity of ATP was also observed in presence of bone marrow stromal cells and its addition to the culture medium enhanced cytosine arabinoside cytotoxicity despite stroma-induced chemoresistance. Xenotransplant experiments confirmed ATP antineoplastic activity in vivo.

Overall, our results demonstrate that P2×7R stimulation by ATP induced a therapeutic response in AML at the LSC level while the normal stem cell compartment was not affected. These results provide evidence that ATP would be promising for developing innovative therapy for AML.

Keywords: acute myeloid leukemia (AML), leukemic stem cell (LSC), P2×7R, ATP, apoptosis

INTRODUCTION

Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder characterized by clonal proliferation of myeloid precursors with an inhibition in differentiation, leading to accumulation of immature cells at various stages. Approximately 50% of leukemia patients survive their disease. The percentage of long-term survivors drops down to 5–15% in elderly patients. Disease relapse and toxicity of therapy, especially in elderly patients, represent today the major limiting factors in leukemia treatment. Despite the introduction of novel target therapies in the treatment of cancer, chemotherapy remains as primary option for AML patients. In this scenario, novel therapeutic approaches that aim to reduce toxicity and to improve the efficacy of treatment are expected to greatly improve long-term outcomes in leukemia patients.

ATP is the key energy currency as well as an ubiquitous extracellular messenger. Depending on its dose and the purinergic P2 receptor (P2R) subtype engaged, ATP can trigger many different cell responses, including cell proliferation, differentiation and apoptosis [1].

Over the past decade, various studies described a direct cytotoxicity of extracellular ATP on different tumor cell types, such as melanoma, glioma and colon cancer cells [13]. ATP acts binding fifteen different purinergic receptors but only five have been described to be involved in ATP direct tumor killing: P2×5R, P2×7R, P2Y1R, P2Y2R and P2Y11R. Among these, P2×7R is the most consistently expressed by tumor cells [4, 5].

P2×7R is an ATP plasma membrane ion channel that, upon transiently stimulation, behaves like a cation-selective channel permeable to Na+, K+ and Ca2+. It shows a growth-promoting activity, which seems to be indispensable for different cell types, such as T lymphocyte or primary mouse microglia cells [69]. One of the most interesting feature of the P2×7R trophic effect is its ability to promote survival and growth in absence of serum [10, 11]. Therefore, it is not surprising that malignant tumors overexpress this receptor. Several groups have described increased expression of P2×7R in prostate [12], breast and skin cancers [13, 14], neuroblastoma [15, 16], leukemia [17, 18] and thyroid papillary carcinoma [19]. This observation, supported by recent studies [20], suggested that P2×7R could have an important role in carcinogenesis and tumor progression [21]. However, P2×7R is an unusual receptor and its massive, unlike tonic low-level, stimulation by ATP leads to the formation of a non selective and permanently opened pore in the cell membrane, triggering cell death signals. Over the past years, several reports showed the possibility to induce tumor inhibition or killing by P2×7R activation [22, 23].

We previously reported that unlike normal CD34+ cells [24], activation of P2R signaling by ATP inhibits leukemic cell functions [18]. Since it has opposite effect on hematopoietic stem cells (HSCs) and leukemic cells, ATP is a good candidate for developing therapies with low toxicity on HSC compartment, which is essential for a complete hematologic recovery after therapy. In the present study, we extended our previous biological findings by testing the therapeutic potential of high dose of ATP in vitro and in vivo. We demonstrated that leukemic stem cells (LSCs) are sensitive to ATP treatment being induced to apoptosis while the same treatment did not affect normal HSC compartment. Moreover, the addition of ATP enhanced the antileukemic activity of cytosine arabinoside and counteracted stroma-mediated chemoresistance. In addition, we demonstrated the in vivo antileukemic effect of ATP treatment. Our data, combined with published studies, suggest the antitumor potential of purinergic-based drugs and propose P2×7R as target for development of therapeutic strategies in leukemia treatment.

RESULTS

P2×7R activation by ATP induces apoptosis of primary AML cells

We first investigated whether ATP, via P2×7R activation, induces apoptosis in primary AML cells. In line with previous report [23], we showed that ATP exerted direct cytotoxicity on AML cells reducing cell viability in a dose dependent manner. This effect is inhibited by P2×7R blockage through the addition of P2×7R antagonist, AZ 10606120 (Figure (Figure1A1A).

Figure 1
ATP triggers apoptosis of leukemia cells from AML patients via P2×7 activation

In order to assess if ATP cell death induction was due to apoptosis, we treated AML cells isolated from 23 AML samples with increasing doses up to 5 mM ATP for 48 h in presence or absence of P2×7R antagonist. As shown in Figure Figure1B,1B, P2X7R activation by 5 mM ATP significantly increased apoptotic AML cells as compared to control (47.5 ± 7.9% vs 26.6 ± 5.8%, p < 0.05). To further confirm P2×7R involvement, we treated AML cells that had previously undergone to P2×7R silencing by short interfering RNAs (siRNA) (Figure (Figure1C).1C). Accordingly, whereas mock-nucleofected cells maintained the capability to respond to ATP stimulation (fold increase of apoptotic cells 2.3 ± 0.5, p < 0.05), cells transduced with anti-P2×7R siRNA failed to respond (Figure (Figure1D),1D), indicating that P2×7R activation is essential for apoptosis.

To better characterize apoptotic process after ATP treatment, we analyzed two specific markers of apoptosis: caspase activity and mitochondrial membrane potential (ΔΨm). To confirm mitochondrial membrane damage after 48 h ATP treatment, we stained AML cells with the cationic lipophilic dye JC-1 which accumulates as aggregates or monomers in healthy or damaged mitochondria, respectively. ATP exposure resulted in ΔΨm reduction in treated as compared to untreated AML cells as demonstrated by the increase of JC1 monomer percentage (32.6 ± 7.5% and 19.5 ± 5.8% respectively, p < 0.05) matched with significant decrease of JC-1 aggregates (75.9 ± 5.3% in treated cells and 59.7 ± 6.1% in untreated cells,p < 0.01). Such process was inhibited by the addition of AZ 10606120 (Figure 2A–2B).

Figure 2
P2×7 activation induces mitochondrial stress and activation of caspase cascade

Then we evaluated caspase cascade activation by analyzing the expression of caspase-3 active form. Immunofluorescence analysis revealed an increased expression of active caspase-3 in AML cells after ATP exposure (Figure (Figure2C).2C). Caspase-3 activation was also confirmed by flow cytometry analysis (Figure 2D–2E). The percentage of active caspase-3+ cells was 12.3 ± 2.0% in untreated cells and 27.3 ± 2.7% in ATP treated cells (p < 0.05), blockage of P2×7R by AZ10606120 restored basal level of caspase-3 activation (13.0 ± 4.4%).

Taken together our results indicate that primary AML cells undergo apoptosis after P2×7R stimulation by high ATP dose through caspase and mitochondria pathways activation.

Bone marrow stroma does not affect ATP treatment efficacy

In the last decade, emerging evidence showed that bone marrow (BM) microenvironment is a key regulator of leukemia growth and its interaction with leukemia cells is one of the cause of chemoresistance [25]. In order to mimic ATP effects on leukemia BM microenvironment, we treated AML cells in presence of normal or leukemic mesenchymal stromal cells (MSCs). Both normal and AML stroma protected AML cells from spontaneous apoptosis, as expected, but did not affect ATP treatment efficacy. Compared to spontaneous apoptosis of blast cells, P2×7R activation with 5 mM ATP induced 1.9 ± 0.3, 1.7 ± 0.4 and 1.5 ± 0.2 fold increase of apoptosis in AML cells cultured alone, with normal MSCs or AML MSCs, respectively (p < 0.05). Blockage of P2×7R by AZ10606120 restored basal level of apoptotic cells in each group (Figure (Figure3A3A).

Figure 3
Stroma cells do not affect antineoplastic activity of ATP

Since P2×7R pore formation facilitates the passage of hydrophilic chemotherapeutic agents [26], we expected to potentiate the cytotoxic effect of antineoplastic drugs and to bypass stroma induced-chemoresistance, by using ATP as adjuvant. We first examined the synergistic effect of combining the cytotoxicity of cytarabine (ARA-C) with the pro-apoptotic activity of ATP. To this end, AML cells were treated for 48 h with increasing doses of ARA-C with or without ATP. As shown in Figure Figure3B,3B, AML cell apoptosis was significantly higher when ATP and ARA-C were combined as compared to their use as single compound (% of Annexin-V+ cells: 4 μM ARA-C+ ATP 78.7 ± 5.3% vs ATP 58.6 ± 5.3% and ARA-C 59.5 ± 5.4%, p < 0.05). Interestingly, the addition of ATP allows to reach a high toxicity using lower doses of ARA-C. We next investigated if the observed synergistic effect was maintained also in presence of a leukemic stroma. Compared to spontaneous apoptosis of leukemic cells, we observed 2.1 ± 0.2 fold change of apoptosis in AML cells treated with ATP plus ARA-C in presence of AML-MSCs (Figure (Figure3C).3C). The increase was significantly higher than AML cells treated with ATP or ARA-C alone in presence of stroma (1.5 ± 0.2 and 1.1 ± 0.2, respectively, p < 0.05).

Taken together, our results demonstrate that ATP antineoplastic activity is maintained also in presence of mesenchymal stromal cell. Moreover, the usage of ATP as adjuvant could bypasses stroma induced-chemoresistance and potentiates ARA-C cytotoxicity.

ATP has direct toxicity on LSCs

Several studies [27, 28] indicate a central role of LSCs in both the genesis and the perpetuation of AML but standard chemotherapy approaches may not effectively target the LSC population. To date there are numerous studies on P2×7R expression by tumor cells, including leukemia cells, but there are no data about its expression on LSCs. In order to investigate the efficacy of ATP treatment in leukemia stem progenitor compartment, we first examined P2×7R expression in four different LSC subsets: CD34-CD38-, CD34+CD38-, CD34+CD38+, CD34-CD38+. Flow cytometric analysis of 22 AML BM samples showed that P2×7R is expressed by all populations analyzed although higher expression was seen in more differentiated progenitor cells (Figure (Figure4A).4A). Next, we tested ATP toxicity on LSC compartment. To this end, we purified LSC populations from 4 AML BM samples, two samples showed > 40% and the other two samples < 20% of P2×7R+ cells in all subsets. Then, we treated them with 5 mM ATP for 48 h. As shown in Figure Figure4B,4B, ATP exposure induced a reduction of viability combined with a cytotoxicity index increase in all subpopulations analyzed. Specifically, percentage of viability and fold change of cytotoxicity index of treated cells were: 60.5 ± 2.5% and 1.6 ± 0.2 for CD34-CD38- cells, 68.5 ± 0.5% and 1.6 ± 0.7 for CD34+CD38- cells, 60.0 ± 10% and 1.5 ± 0.2 for CD34+CD38+ cells, 61.5 ± 27.5% and 2.1 ± 0.5 for CD34CD38+. Similarly to total AML cells (Figure (Figure1),1), increased cytotoxicity was due to induction of apoptosis as demonstrated by increased caspase-3/7 activity. Interestingly, also primitive progenitors, which express lower level of P2×7R, showed sensitivity to ATP-mediated cytotoxicity, thus suggesting that ATP may act also on cells with reduced P2×7R expression.

Figure 4
ATP exerts a direct toxicity on LSCs

Taken together our results demonstrate that ATP treatment is effective at inducing toxicity not only in leukemic blasts but, more importantly, also in LSCs.

High dose ATP does not affect normal hematopoietic stem cell compartment

Along with the identification of drugs which eradicate leukemia at the level of LSCs, minimizing the toxicity of antineoplastic agents on the normal HSC compartment represents a major task. In order to test ATP cytotoxicity on HSC compartment, normal CD34+ cells were treated with increasing doses of ATP, under the same culture conditions used for AML cells. Interestingly, this treatment readily reduced viability and induced apoptosis of AML cells, whereas normal CD34+ cells were almost entirely unaffected (Figure 5A–5B). Analysis of AML sample at the highest ATP concentration showed an average viability of 54.8 ± 9.2 % after 48h ATP exposure. In contrast, normal CD34+ samples showed an average viability of 92.5 ± 0.5 % when analyzed by using the same condition (p < 0.05). We also tested the ATP treatment on normal HSC subsets. Based on the gating strategies used for AML samples and illustrated in Figure Figure5,5, we separated four progenitor subpopulations from 3 normal BM samples and tested their ability to respond to ATP treatment. Conversely to LSC subsets, normal hematopoietic progenitors showed no variation in cell viability after high ATP dosage exposure (Figure (Figure5C5C).

Figure 5
HSCs were almost entirely unaffected by ATP treatment

These results provide evidence that high ATP dosage does not impair normal stem cell compartment, which is an essential aspect for a complete hematologic recovery after therapy.

In vivo ATP administration reduces leukemia cell growth

To asses if ATP antitumor effect observed in vitro also occurs in vivo, we investigated the pharmacologic effect of ATP administration in xenotransplanted mice. We used two experimental groups (Figure (Figure6A).6A). In the first one, we assessed the effect of ATP treatment on freshly implanted leukemia by administrating ATP starting the day after tumor inoculation. In the second one, the change in rate of growth of an established leukemia after ATP treatment was assessed. The same therapeutic regimen was used, but treatment was commenced once human engraftment was greater than 0.1% in peniferal blood of mice. As shown in Figure Figure6B,6B, we observed a reduction of about 40% of human leukemia engraftment three months after the end of treatment, in both experimental groups (percentage of human engraftment: 57.3 ± 13.0% and 65.5 ± 5.4%, in first and second group respectively. p < 0.01), in agreement with the results from in vitro experiments. At necroscopy, control mice had enlarged spleen in comparison to ATP treated groups (Figure (Figure6C).6C). Treatment was well tolerated as suggested by the maintenance of body weight and the lack of toxicity primary signs, such as lethargy, ruffled fur, respiratory distress and hunchback posture (data not shown).

Figure 6
ATP administration reduces leukemia cell growth in NSG mice

These results indicate that in vivo ATP administration is well tolerated and efficiently reduce leukemia cell growth, therefore they provide solid evidence for the further evaluation of ATP in clinical trials.

DISCUSSION

LSCs resistance to current therapies as well as treatment-related toxicity are the main cause of failure in AML patients especially if elderly. More than 70% of AML occur in adults aged > 60 years, who are often unable to receive chemotherapy and whose prognosis is, consequently, poor [29, 30]. Therefore, the development of therapeutic approaches that target LSC population minimizing toxicity on HSCs, essential for a complete hematological recovery after treatment, is highly warranted.

There is growing interest in the therapeutic potential of purinergic signaling for the treatment of cancer [31]. After the first reports by Rapaport in 1983 who demonstrated that exogenous ATP inhibited cell growth of adenocarcinomatous pancreatic and colon cancer cells [32], subsequent papers have shown an anti-tumoral effect of extracellular nucleotides in various cancer cell types [31]. Interestingly, our recent studies reported that ATP exerts opposite effects on HSCs and AML cells [24]. However, the complete picture is probably more complicated and could be dependent upon the kind of malignancy analyzed. Purinergic receptors like P2×7R have been shown to promote cancer growth and progression in certain conditions [21, 33] while, in some case, to partially prevent cancer growth by immune infiltration [34, 35].

In the present study, we sought to investigate the use of ATP for P2×7R pro-apoptotic signaling activation specifically on LSCs. We demonstrated that AML cells exposed to high ATP dosage show a reduced viability and undergo apoptosis, as demonstrated by the increased mitochondrial permeability and by activation of caspase cascade. In line with previous reports on cell lines [22, 23], we confirmed that ATP cytotoxicity is mediated by P2×7R activation on primary leukemia cells.

BM microenvironment has an important role in several aspects of AML, including development, progression and resistance to chemotherapy [36]. To better analyze the antineoplastic effect of ATP, we tested the treatment by co-culturing AML cells with MSCs, thus mimicking BM microenvironment. Several pro-survival and anti-apoptotic signals in AML cells are activated by the stroma [37], including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) [38, 39] pathway (PI3K/AKT/mTOR), which weaken the response of leukemic cells to conventional chemotherapy. Since it was described that P2×7R activation by ATP leads to a concurrent blockade of the mTOR signalling [22], we hypothesized that ATP treatment could interfere in stroma-induced anti-apoptotic signals in AML cells. Interestingly, we observed that both normal and AML-derived stroma did not affect the pro-apoptotic ATP effect on leukemia blasts, suggesting that potential therapeutic treatment with ATP could bypass stroma-mediated AML resistance. Moreover, considering that P2×7R pore formation facilitates the passage of hydrophilic chemotherapeutic agents [26], we hypothesized that the addition of ATP would counteract stroma induced-chemoresistance and would potentiate the cytotoxic effect of chemotherapeutics. The principle of combined therapy is to maximize antineoplastic activity while minimizing toxic side effect of treatment. This is best attained by combining drugs with different mechanisms of action. We demonstrated that ATP combined with ARA-C significantly increases its effect on cell death and reduces the chemotherapeutic drug concentration needed to obtain high level of cytotoxicity on leukemia cells, also in presence of a stroma. These data may have interesting clinical implications for the management of frail elderly AML individuals, generally unfit to chemotherapy at standard dosage. Indeed, the use of ATP as adjuvant to conventional chemotherapeutics may allow to reduce their dosage and toxicity, while maintaining their therapautic efficacy.

Despite the accumulating evidence that P2×7R is overexpressed by tumor cells, no data are available about its expression on LSCs. We report for the first time that leukemic stem progenitor subsets express P2×7R and interestingly its activation by high ATP dose effectively affects LSCs viability, inducing apoptosis. In contrast, HSCs appear to be resistant to the same treatment. These findings clearly demonstrate that activation of the same receptor by ATP on normal and leukemic cells could selectively target LSCs and it represents a good premise for the development of new therapeutic strategies. Although the underlying mechanism of this opposite effect is not yet clarified, our hypothesis is that a differential expression of P2×7R isoform on normal and leukemic cells may occur. Nine different human splice variants of P2×7R receptor have been identified (P2×7RA-J), four of these lack the extended C-terminal tail typical of the full-length receptor (P2×7RA) [40, 41]. Among the truncated splice variants, P2×7RB exerts a trophic activity in HEK293 cells, losing the pro apoptotic function of P2×7RA. Interestingly, P2×7RB acts as dominant positive subunit by enhancing all its known functions, including apoptotic pore opening and cell growth, when co-expressed with P2×7RA [42]. Moreover, P2×7RA and P2×7RB isoforms have differential effects on cell growth and on mineralization of osteosarcoma cells [43]. We demonstrated that in normal HSCs P2×7RB is the predominant isoform (manuscript in preparation) and even if high ATP concentrations will occur, they fail to cause pore formation. The preferential expression of P2×7RB in normal CD34+ could be one of the mechanism by which HSCs sense the high ATP concentration in site of inflammation as growth stimulus, protecting themselves from apoptosis.

In keeping with in vitro experiments, we demonstrated that ATP antineoplastic effect also occurs in vivo. ATP administration significantly reduced human leukemia growth in NSG mice, without causing any adverse side effects in treated animals. The present results are the first evidence of the efficacy of ATP treatment in haematological malignancies in vivo and they are in line with those described in murine models of solid tumors, such as colon and pancreatic cancer [44], melanoma [45], bladder [46] and prostate [47] cancer. In our in vivo experiments, high ATP concentration has been used to level that exceeds the dose permitted in humans. However, since murine blood has higher ecto-ATPase activity in vitro compared to human blood [46] thus leading to a greater breakdown of ATP, we would expect to obtain the same therapeutic effect in patients by using a lower concentration.

Several clinical application of extracellular ATP have been reported in several fields, including oncology [4852]. Studies from Agteresch [49, 50, 52] demonstrated the safety of ATP infusion in patient with lung cancer. ATP treatment was well tolerated and if side effects occur, they were mild and transient. In randomised trials, overall survival time of patients with advanced stage IIIB non-small cell lung cancer increased from 9.3 months in the ATP-treated vs 3.5 months for the control group. Furthermore, Beijer and colleagues showed that, in contrast to many conventional antitumor regimens, ATP infusions may have a beneficial effect on survival without negatively affecting quality of life of cancer patients affected by various solid tumors [48, 51]. It has also been demonstrated that ATP administration reduced disease activity and inflammation in a patient with active rheumatoid arthritis [53].

In conclusion, P2×7R stimulation by ATP induced a therapeutic response in blasts from AML patients and more importantly in LSCs, while did not affect HSC compartment. Moreover ATP potentiated the cytotoxic effect of chemotherapic drugs, allowing to reduce their dose. Murine model confirmed the antileukemic activity in vivo.

These results provide evidence that ATP would be effective and promising for developing innovative therapy for AML.

MATERIALS AND METHODS

Cell isolation and culture

Primary leukemic cells were obtained from peripheral or bone marrow blood of 34 AML patients at diagnosis, before treatment (Supplementary Data, Supplementary Table S1). The percentage of leukemic blasts was always > 90%. Normal mononuclear cells (MNCs) were obtained from BM healthy donors. Mononuclear cells were isolated by Ficoll-Hypaque centrifugation (Amersham Bioscience, Piscataway, NJ, USA). In some experiments, normal PB MNCs were processed by MiniMacs high-gradient magnetic separation column (Miltenyi Biotec, Bergisch Gladbach, Germany) to obtain highly purified CD34+ cells.

For in vitro studies, cells were cultured in RPMI 1640 medium supplemented with 10% FBS (GIBCO, Thermo Fisher Scientific, MA, USA) in presence of increasing dose of ATP (Sigma Aldrich, Germany) and ARA-C (Sigma Aldrich). In some experiments, cells were pre-treated for 30 min at 37°C with 10 μM AZ 10606120, a P2×7R specific antagonist (Tocris, Bristol, United Kingdom).

The pH of ATP solution was adjusted to 6.8 using NaOH for both in vitro and in vivo experiments.

The research was approved by the Ethics Committee of Policlinico S.Orsola-Malpighi, University Hospital of Bologna and each individual gave written informed consent (Ethical Committee approval code: 147/2013/O/Tess).

Viability assay

CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega Corporation, Madison, WI, USA) was used to detect cell viability. Five × 105 cells/100 μl culture medium were seeded into 96-well microplate and treated as indicated. After culture, CellTiter 96 AQueous One Solution reagent was added to each well and the microplate was incubated for 4 h at 37°C in 5% humidified CO2. Optical density value was measured by an ELISA plate reader (Multiskan Ex, Thermo Electron Corporation, San Josè, CA, USA) at a wavelength of 492 nm. Each variant group was performed in triplicate wells.

Apoptosis

Apoptosis was measured with Annexin-V-FLUOS Staining Kit (Roche, Mannheim, Germany) followed by flow cytometric analysis (BD AccuriTM C6, BD Becton Dickinson, NJ USA. FCS Express 4 Software, De Novo Software, Los Angeles, CA USA). After the indicated treatment, cells were harvested and stained according to manufacturer's instructions. Briefly, 1 × 106 cells were resuspended in 100 μl Incubation Buffer, stained with 2 μl FITC-conjugated Annexin-V and 2 μl propidium iodide (PI) for 10 min at room temperature and analyzed. Results were compared to the apoptotic rate of untreated cells.

siRNA transfection of AML cells

AML cells were transfected with 350 nM SMARTpool ON-TARGETplus P2RX7 siRNA (Dharmacon, Lafayette, CO), using standard Nucleofector Amaxa Thecnology (Amaxa Biosystem, Germany) [54]. Briefly, 2 × 106 AML cells were transfected by using the U08 program. The target sequences were: i) GCGGUUGUGUCCCGAGUAU, ii) GGAUCCAGAGCAUGAAUUA, iii) GCUUUGCUCUG GUGAGUGA, iiii) GGAUAGCAGAGGUGAAAGA. ON-TARGETplus Non-targeting Control Pool designed and tested for minimal targeting of human genes was used as negative control (Dharmacon). After 24 h incubation, AML cells were treated with 5 mM ATP with or without 10 μM AZ 10606120 for 24 h.

Active caspase-3 expression

Flow cytometric analysis of active caspase-3 was performed using Fixation Permeabilization kit (BD) for intracellular staining and human active Caspase-3-PE monoclonal antibody (BD), according to protocol's instruction. BD AccuriTM C6 cytometer and FCS Express 4 Software were used.

For immunofluorescence staining, cells were fixed in 4% parafolmaldehyde and permeabilized with 0.25% Triton. The staining was performed using anti-Human CASP3 monoclonal antibody (Invitrogen, CA USA) and anti-Rabbit FITC secondary antibody (Dako, Denmark). Cell were examined under fluorescence Axiovert microscope with a CCD camera (Zeiss, Germany)

Mitochondrial membrane potential measurement

The variation in ΔΨm was investigated using the BD MitoScreen Kit (BD) according to the manufacturer's instruction. Briefly, 1 × 106 cells were harvested from the suspension cultures, washed twice with PBS and incubated with JC-1 solution for 15 min at 37°C. JC-1 monomers or aggregates were analyzed by flow cytometry (BD AccuriTM C6 cytometer and FCS Express 4 Software).

Co-culture of AML cells with MSCs

Normal or AML MSCs, isolated as previously described [55], were seeded in 96 well plates 1 × 104/well, AML cells were added to the confluent layer at 10:1 ratio. After overnight incubation, cells were treated as indicated. After 48 h treatment, AML cells were harvested for analysis, leaving MSC stroma intact.

Flow cytometry and cell sorting

P2×7R expression in LSC subsets was analyzed by flow cytometry (BD AccuriTM C6 cytometer and FCS Express 4 Software). BM cells from 22 AML samples were labelled with an anti-P2×7R FITC (Alomone Labs, Israel), anti-CD34 APC (BD) and Anti-CD38 PE (BD) monoclonal antibodies.

Leukemic and normal stem/progenitor cell subset were purified by cell sorting strategy. BM MNCs were stained with human CD34-FITC and CD38-APC monoclonal antibodies (BD) and sorted on FACSAria (BD). Aliquots of sorted populations were reanalyzed to assess their purities, which were always found to be greater than 98%.

Caspase-3/7 activity assay

ApoTox-Glo Triplex Assay (Promega) was used to assess cytotoxicity and caspase-3/7 activity in LSC subsets. Cells were plated in 96-well plate (2,000 cells/100 μl /well) and treated with 5 mM ATP for 48 h. At the end of culture, according to protocol's instruction, we added 20 μl of Viability/Cytotoxicity Reagent to each well. After 30 min incubation at 37°C, cell viability and cytotoxicity (wavelength 400Ex/505Em, 485Ex/520Em respectively) were assessed by measuring fluorescence with Victor2 Microplate Reader (Perkin Elmer, MA USA). After the measurement of cell viability, the caspase-Glo 3/7 reagent was added into each well, the plates were briefly mixed by an orbital shaker and incubated for 30 min at 37°C. Caspase-3 activation was determined by measuring luminescence with Victor2 Microplate Reader. Each variant group was performed in triplicate wells.

Xenotransplant experiments

Experiments were carried out on nonobese diabetic severe combined immunodeficient (NOD/SCID) interleukin-2 receptor g (IL-2Rg)–null (NSG) mice, 6 to 8-weeks-old. NSG mice were bred and housed under pathogen-free conditions in the animal facilities at the European Institute of Oncology–Italian Foundation for Cancer Research (FIRC) Institute of Molecular Oncology (IEO-IFOM, Milan, Italy). All animal experiments were done in accordance with the Italian Laws (D.L.vo 26/2014 and following additions), and institutional guidelines, and were approved by the Italian Ministry of Health. For induction of human leukemia, 1 × 106 AML cells were injected intravenously through the lateral tail vein of sublethally irradiated mice. Primary cells from 4 different AML patients were used.

Two experimental treatment design were used. In the first group, one day after cell transfer 50 mM ATP in 0.25 ml sterile saline was administered for 30 days, every other day by i.p. injection. In the second group, the same therapeutic regime was used as before, but the treatment started once AML was established. A control group (CTR) received i.p. an equivalent volume of the vehicle (sterile saline solution). Five mice were randomly picked and assigned to each experimental group. Human cell engraftment in the peripheral blood from tail vein was investigated by flow cytometry. Cells were stained with anti-human CD45-APC (Beckman-Coulter, CA, USA) and anti-mouse CD45-PE (BD) antibodies. After red cell lysis, cell suspensions were evaluated by a FACSCalibur (BD). Seven-aminoactinomycin D (7AAD; Sigma-Aldrich) was used to enumerate viable, apoptotic and dead cells.

Statistical analysis

Results are expressed as means ± SEM

Depending on experimental conditions, statistical analysis will be performed using t test or ANOVA followed by a post hoc test (Bonferroni or Dunnet’s) (GraphPad Prism, version 6.03). P < 0.05 was considered statistically significant.

SUPPLEMENTARY MATERIALS AND TABLES

Acknowledgments

We are grateful to all patients who participated.

Footnotes

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This research was supported by the Italian Ministry of Education, University and Research (MIUR; RBAP11FXBC_003). This work was also supported by Associazione Italiana contro le Leucemie Bologna section, Fondazione CARISBO (Cassa di Risparmio in Bologna), and Fondazione FATRO (Farmotecnica Romagnola), EA was supported by grants from AIRC (MFAG 11630 and IG16812).

REFERENCES

1. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci. 2006;27:211–217. [PubMed]
2. Souza CO, Santoro GF, Figliuolo VR, Nanini HF, de Souza HS, Castelo-Branco MT, Abalo AA, Paiva MM, Coutinho CM, Coutinho-Silva R. Extracellular ATP induces cell death in human intestinal epithelial cells. Biochim Biophys Acta. 2012;1820:1867–1878. [PubMed]
3. Shabbir M, Burnstock G. Purinergic receptor-mediated effects of adenosine 5′-triphosphate in urological malignant diseases. Int J Urol. 2009;16:143–150. [PubMed]
4. Adinolfi E, Capece M, Amoroso F, De Marchi E, Franceschini A. Emerging roles of P2X receptors in cancer. Curr Med Chem. 2015;22:878–890. [PubMed]
5. Di Virgilio F. Purines, purinergic receptors, and cancer. Cancer Res. 2012;72:5441–5447. [PubMed]
6. Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P, Hanau S, Chiari E, Rubini M, Di Virgilio F. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood. 1996;87:682–690. [PubMed]
7. Bianco F, Ceruti S, Colombo A, Fumagalli M, Ferrari D, Pizzirani C, Matteoli M, Di Virgilio F, Abbracchio MP, Verderio C. A role for P2×7 in microglial proliferation. J Neurochem. 2006;99:745–758. [PubMed]
8. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel PA, Junger WG. Autocrine regulation of T-cell activation by ATP release and P2×7 receptors. Faseb J. 2009;23:1685–1693. [PubMed]
9. Monif M, Reid CA, Powell KL, Smart ML, Williams DA. The P2×7 receptor drives microglial activation and proliferation: a trophic role for P2×7R pore. J Neurosci. 2009;29:3781–3791. [PubMed]
10. Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G, Di Virgilio F. Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem. 1999;274:33206–33208. [PubMed]
11. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR, Pinton P, Rizzuto R, Di Virgilio F. Basal activation of the P2×7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005;16:3260–3272. [PMC free article] [PubMed]
12. Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA. Early prostate cancer detected using expression of non-functional cytolytic P2×7 receptors. Histopathology. 2004;44:206–215. [PubMed]
13. Slater M, Danieletto S, Pooley M, Cheng Teh L, Gidley-Baird A, Barden JA. Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res Treat. 2004;83:1–10. [PubMed]
14. Greig AV, Linge C, Healy V, Lim P, Clayton E, Rustin MH, McGrouther DA, Burnstock G. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J Invest Dermatol. 2003;121:315–327. [PubMed]
15. Raffaghello L, Chiozzi P, Falzoni S, Di Virgilio F, Pistoia V. The P2×7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res. 2006;66:907–914. [PubMed]
16. Amoroso F, Capece M, Rotondo A, Cangelosi D, Ferracin M, Franceschini A, Raffaghello L, Pistoia V, Varesio L, Adinolfi E. The P2×7 receptor is a key modulator of the PI3K/GSK3beta/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene. 2015;34:5240–5251. [PubMed]
17. Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A, Cuneo A, Castoldi G, Di Virgilio F, Baricordi OR. P2×7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood. 2002;99:706–708. [PubMed]
18. Salvestrini V, Zini R, Rossi L, Gulinelli S, Manfredini R, Bianchi E, Piacibello W, Caione L, Migliardi G, Ricciardi MR, Tafuri A, Romano M, Salati S, et al. Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood. 2012;119:217–226. [PubMed]
19. Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari MG, Dardano A, Faviana P, Madec S, Di Virgilio F, Monzani F. Increased P2×7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology. 2008;149:389–396. [PubMed]
20. Hattori F, Ohshima Y, Seki S, Tsukimoto M, Sato M, Takenouchi T, Suzuki A, Takai E, Kitani H, Harada H, Kojima S. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2×7. Eur J Pharmacol. 2012;695:20–26. [PubMed]
21. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V, Di Virgilio F. Expression of P2×7 receptor increases in vivo tumor growth. Cancer Res. 2012;72:2957–2969. [PubMed]
22. Bian S, Sun X, Bai A, Zhang C, Li L, Enjyoji K, Junger WG, Robson SC, Wu Y. P2×7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death. PLoS One. 2013;8:e60184. [PMC free article] [PubMed]
23. Zhang X, Meng L, He B, Chen J, Liu P, Zhao J, Zhang Y, Li M, An D. The role of P2×7 receptor in ATP-mediated human leukemia cell death: calcium influx-independent. Acta Biochim Biophys Sin (Shanghai) 2009;41:362–369. [PubMed]
24. Rossi L, Salvestrini V, Ferrari D, Di Virgilio F, Lemoli RM. The sixth sense: hematopoietic stem cells detect danger through purinergic signaling. Blood. 2012;120:2365–2375. [PubMed]
25. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114:1150–1157. [PubMed]
26. Alves LA, Bezerra RJ, Faria RX, Ferreira LG, da Silva Frutuoso V. Physiological roles and potential therapeutic applications of the P2×7 receptor in inflammation and pain. Molecules. 2013;18:10953–10972. [PubMed]
27. Jordan CT. The leukemic stem cell. Best Pract Res Clin Haematol. 2007;20:13–18. [PMC free article] [PubMed]
28. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 2009;23:25–42. [PMC free article] [PubMed]
29. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908–1915. [PubMed]
30. Sanford D, Ravandi F. Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions. Drugs Aging. 2015;32:983–997. [PubMed]
31. Burnstock G, Di Virgilio F. Purinergic signalling and cancer. Purinergic Signal. 2013;9:491–540. [PMC free article] [PubMed]
32. Rapaport E. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J Cell Physiol. 1983;114:279–283. [PubMed]
33. Giannuzzo A, Pedersen SF, Novak I. The P2×7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer. 2015;14:203. [PMC free article] [PubMed]
34. Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano D, Pinton P, Jorgensen NR, Abelli L, et al. Accelerated tumor progression in mice lacking the ATP receptor P2×7. Cancer Res. 2015;75:635–644. [PubMed]
35. Hofman P, Cherfils-Vicini J, Bazin M, Ilie M, Juhel T, Hébuterne X, Gilson E, Schmid-Alliana A, Boyer O, Adriouch S, Vouret-Craviari V. Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer. Cancer Res. 2015;75:835–845. [PubMed]
36. Rashidi A, DiPersio JF. Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence. Ther Adv Hematol. 2016;7:40–51. [PMC free article] [PubMed]
37. Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, et al. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012;120:2679–2689. [PubMed]
38. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007;67:684–694. [PubMed]
39. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002;16:1713–1724. [PubMed]
40. Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder S. Identification and characterization of splice variants of the human P2×7 ATP channel. Biochem Biophys Res Commun. 2005;332:17–27. [PubMed]
41. Feng YH, Li X, Zeng R, Gorodeski GI. Endogenously expressed truncated P2×7 receptor lacking the C-terminus is preferentially upregulated in epithelial cancer cells and fails to mediate ligand-induced pore formation and apoptosis. Nucleosides Nucleotides Nucleic Acids. 2006;25:1271–1276. [PubMed]
42. Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, Callegari MG, Sandonà D, Markwardt F, Schmalzing G, Di Virgilio F. Trophic activity of a naturally occurring truncated isoform of the P2×7 receptor. Faseb J. 2010;24:3393–3404. [PubMed]
43. Giuliani AL, Colognesi D, Ricco T, Roncato C, Capece M, Amoroso F, Wang QG, De Marchi E, Gartland A, Di Virgilio F, Adinolfi E. Trophic activity of human P2×7 receptor isoforms A and B in osteosarcoma. PLoS One. 2014;9:e107224. [PMC free article] [PubMed]
44. Rapaport E. Experimental cancer therapy in mice by adenine nucleotides. Eur J Cancer Clin Oncol. 1988;24:1491–1497. [PubMed]
45. White N, Knight GE, Butler PE, Burnstock G. An in vivo model of melanoma: treatment with ATP. Purinergic Signal. 2009;5:327–333. [PMC free article] [PubMed]
46. Shabbir M, Ryten M, Thompson C, Mikhailidis D, Burnstock G. Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int. 2008;101:106–112. [PubMed]
47. Shabbir M, Thompson C, Jarmulowiczc M, Mikhailidis D, Burnstock G. Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU Int. 2008;102:108–112. [PubMed]
48. Beijer S, Hupperets PS, van den Borne BE, Eussen SR, van Henten AM, van den Beuken-van Everdingen M, de Graeff A, Ambergen TA, van den Brandt PA, Dagnelie PC. Effect of adenosine 5’-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Anticancer Drugs. 2009;20:625–633. [PubMed]
49. Agteresch HJ, Dagnelie PC, Rietveld T, van den Berg JW, Danser AH, Wilson JH. Pharmacokinetics of intravenous ATP in cancer patients. Eur J Clin Pharmacol. 2000;56:49–55. [PubMed]
50. Agteresch HJ, Burgers SA, van der Gaast A, Wilson JH, Dagnelie PC. Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs. 2003;14:639–644. [PubMed]
51. Beijer S, Hupperets PS, van den Borne BE, Wijckmans NE, Spreeuwenberg C, van den Brandt PA, Dagnelie PC. Randomized clinical trial on the effects of adenosine 5′-triphosphate infusions on quality of life, functional status, and fatigue in preterminal cancer patients. J Pain Symptom Manage. 2010;40:520–530. [PubMed]
52. Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:321–328. [PubMed]
53. Bours MJ, Peeters RH, Landewe RB, Beijer S, Arts IC, Dagnelie PC. Adenosine 5’-triphosphate infusions reduced disease activity and inflammation in a patient with active rheumatoid arthritis. Rheumatology (Oxford) 2010;49:2223–2225. [PubMed]
54. Aluigi M, Fogli M, Curti A, Isidori A, Gruppioni E, Chiodoni C, Colombo MP, Versura P, D’Errico-Grigioni A, Ferri E, Baccarani M, Lemoli RM. Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells. 2006;24:454–461. [PubMed]
55. Ferrari D, Gulinelli S, Salvestrini V, Lucchetti G, Zini R, Manfredini R, Caione L, Piacibello W, Ciciarello M, Rossi L, Idzko M, Ferrari S, Di Virgilio F, et al. Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Exp Hematol. 2011;39:360–374. 374.e361–365. [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC